Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com
  • 5.0 (1)
  • Health & Fitness

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. 1d ago

    Could Eye Blood-Flow Scans Predict Glaucoma Progression Better Than Regular OCT? New 4-Year Results

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/could-eye-blood-flow-scans-predict-glaucoma-progression-better-than-regular-oct-new-4-year-results Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Could Eye Blood-Flow Scans Predict Glaucoma Progression Better Than Regular OCT? New 4-Year Results Short answer: Optical coherence tomography angiography (OCTA) may reveal glaucoma-related change when conventional retinal thickness measurements are no longer changing clearly—especially in some eyes with advanced glaucoma. But the new study does not prove that OCTA is superior to structural optical coherence tomography (OCT). It found an association between faster vessel-density loss and visual-field progression; it did not make a formal comparison of how well the two tests predict progression, and important methodological details are not available in the abstract. A key wording point: OCTA is not a direct blood-flow meter. It detects a signal from moving blood cells and maps vessels that are flowing fast enough to be detected. A falling vessel-density reading may reflect reduced flow signal, capillary loss, image quality, or a combination of these—not necessarily vessels physically disappearing. American Academy of Ophthalmology OCTA assessment What the October 28, 2026 study found The study, “Longitudinal OCT Angiography Versus Structural OCT for Predicting Visual Field Progression in Glaucoma,” was published in the Journal of Glaucoma on October 28, 2026. It followed 333 eyes with open-angle glaucoma, including 110 eyes with normal-tension glaucoma, for an average of 4.1 years. The reported results support OCTA as a potentially useful additional monitoring signal—but do not establish that it should replace OCT or visual-field testing. Journal of Glaucoma article record What can—and cannot—be reconstructed The study’s accessible abstract reports that it was a prospective study. The glaucoma eyes were followed quarterly; 60 age-matched healthy control eyes were examined at the start and again after six months. The researchers tracked: Peripapillary capillary vessel density: the capillary signal around the optic nerve. Macular vessel density: the capillary signal in the central retina, including the parafoveal area. Peripapillary retinal nerve fiber layer thickness: a structural OCT measurement around the optic nerve. Macular ganglion cell–inner plexiform layer thickness: a structural OCT measurement of retinal cells important to vision. Visual-field progression: worsening in the patient’s measured field of vision. The researchers compared change rates with linear mixed-effects models and used multivariable Cox models with cumulatively updated change rates as time-dependent predictors. Visual-field progression was described as being determined with combined event-based and trend-based criteria. Journal of Glaucoma article record There is an important limit to what can be verified: the accessible abstract does not provide the scan device, exact visual-field criteria, glaucoma-stage definitions, full list of model adjustments, or all numerical results. It also does not give confidence intervals for the structural-OCT hazard ratios or the rates of change in the healthy controls. I could not verify those details from a full Methods section or supplement for this review. They should not be guessed. The reported numerical results For the full table, please open this article on visualfieldtest.com. The macular vessel-density loss rates differed by 0.72 percentage points per year between progressors and nonprogressors; the peripapillary rates differed by 0.17 percentage points per year. The hazard ratios mean that, in the model, faster vessel-density loss was associated with a higher rate of visual-field progression. They do not tell a patient’s absolute chance of losing vision, and they do not show that a vessel-density change caused the field loss. The retinal nerve fiber layer and ganglion-cell layer rates were not statistically significant independent predictors in the reported adjusted models. That does not prove that structural OCT is useless, nor does it prove OCTA is better. A significant result for one measure and a nonsignificant result for another is not, by itself, a formal statistical test that one test outperforms the other. The abstract says the Cox models were multivariable, but it does not identify the adjustment variables. Therefore, it is not possible to confirm from the accessible report whether the vessel-density associations remained after accounting for blood pressure, age, glaucoma severity, signal quality, cataract, myopia, or other factors. Nor can the inclusion of 110 normal-tension glaucoma eyes establish a specific OCTA benefit for that subgroup: separate normal-tension results are not provided in the abstract. Journal of Glaucoma article record Why OCTA may add information when structural OCT appears flat Structural OCT can reach a measurement floor Structural OCT measures tissue thickness. In advanced glaucoma, the retinal nerve fiber layer can become so thin that much of the remaining signal comes from non-neural tissue, such as glial tissue and blood vessels. Further nerve-cell damage may then produce little measurable change in the thickness number—a measurement floor. The floor varies by device and measurement method. In one advanced-glaucoma study, average peripapillary nerve fiber layer measurements reached an estimated floor around a visual-field mean deviation of −17.5 decibels, while some macular vessel-density measures remained measurable at more severe field loss. Other studies have found that some macular ganglion-cell tissue remains above its floor in parts of the retina even when the peripapillary nerve fiber layer is near its floor. So the practical point is not that all structural OCT fails in advanced disease: macular ganglion-cell measurements may continue to help, depending on the eye and the region measured. OCT/OCTA floor study Structural OCT floor study Vessel-density measures may retain a signal deeper into disease—but are not floor-proof Some OCTA measurements have shown a longer usable range into severe disease than thickness measurements. In one analysis, parafoveal vessel density had no detectable floor within the study’s observed range, while structural nerve fiber and ganglion-cell measures showed floors at less severe visual-field loss. But a different study found that OCTA measures often had fewer reliable measurement steps across their full range than structural OCT measures, partly because OCTA has its own test–retest variability. The result is a trade-off: OCTA may remain measurable later, but that does not automatically make it easier to detect a small, genuine change. OCTA and OCT measurement-floor comparison OCTA measurement-floor study The scan measures a vascular signal, not the health of a nerve cell directly OCTA can show a change in capillary signal in a retinal region where thickness values are stable. That may be useful because retinal ganglion cells and their nerve fibers depend on blood supply, and capillary signals can change without a measurable change in the thickness of the tissue being scanned. But OCTA does not directly measure oxygen delivery, blood-flow volume, or whether each nerve cell is alive. A reduction in its signal may occur because flow has slowed below the instrument’s detection threshold, because capillary pathways have changed, or because of image artifacts. A “vessel-density loss” should therefore be read as a change in the scan’s flow-related vascular signal—not as a literal count of vanished blood vessels. American Academy of Ophthalmology OCTA assessment Do vascular changes cause nerve damage, or follow it? Both explanations are plausible, and current clinical imaging studies do not settle the question. Hypothesis 1: reduced or unstable blood supply contributes to nerve injury The retina and optic nerve need a steady supply of oxygen and energy. If blood supply becomes inadequate or poorly regulated, nerve cells may be more vulnerable to stress. Blood-pressure changes, low ocular perfusion pressure, and impaired vascular autoregulation have all been investigated in glaucoma. A vascular contribution could be particularly relevant in normal-tension glaucoma, where damage occurs even without a high measured eye pressure. Longitudinal studies showing vessel-density change before later visual-field change fit this hypothesis, but they do not prove it. An earlier scan change may indicate that vascular stress is part of the disease process—or simply that the vascular measure detects damage earlier than a later test. Review of the retinal neurovascular unit in glaucoma American Academy of Ophthalmology Preferred Practice Pattern Hypothesis 2: damaged nerve cells need less blood The opposite direction is also reasonable: if retinal nerve cells are damaged or less active, they may need less energy and therefore less blood supply. Capillary signals could decline because the neural tissue is already deteriorating. Under this explanation, OCTA is an indirect marker of injury rather than a cause of it. Most likely: the relationship is mixed and may run both ways The evidence is consistent with a coupled process: vascular regulation and nerve-cell health may influence one another, while glaucoma and other patient factors affect both. Importantly, a scan showing a vascular Support the show

    Could Eye Blood-Flow Scans Predict Glaucoma Progression Better Than Regular OCT? New 4-Year Results

  2. 5d ago

    Once Glaucoma Starts Progressing, How Hard Is It to Stop? A New 12-Year Study Gives an Answer

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/once-glaucoma-starts-progressing-how-hard-is-it-to-stop-a-new-12-year-study-gives-an-answer Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Once Glaucoma Starts Progressing, How Hard Is It to Stop? A New 12-Year Study Gives an Answer A first confirmed visual-field progression event is a warning—not a guarantee that vision will keep worsening. But a large, long-running study from Bascom Palmer Eye Institute suggests that a meaningful share of eyes do progress again, even while receiving routine care. Published online in JAMA Ophthalmology on October 22, 2026, the study found that recurrence was more likely when vision had been declining quickly before the first event and when average eye pressure remained higher afterward. More pressure reduction was associated with less recurrence, but this was an observational study: it cannot prove that treatment escalation caused the difference. () What the Bascom Palmer study measured Researchers reviewed records from 7,457 eyes belonging to 5,086 people with open-angle glaucoma or suspected glaucoma. The records spanned 1998 to 2025. Across the full group, average follow-up was 12.4 years, with an average of 12.3 visual-field tests per eye. A visual-field test measures how well a person sees in different parts of their field of vision. The first progression analysis included all 7,457 eyes. The recurrence analysis was narrower: 1,951 eyes had an initial “likely progression” event, but only 635 had enough later visual-field tests and eye-pressure records for the researchers to assess recurrence. The recurrence results therefore describe this smaller, well-monitored group—not every eye in the original registry. () How the study defined a progression event The researchers used Guided Progression Analysis, a tool for comparing visual-field test results over time. It compares later tests with the average of the first two reliable tests and looks for worsening at the same test locations beyond the amount expected from normal test-to-test variation. An eye met the study’s definition of “likely progression” when three or more of the same locations worsened on three consecutive examinations. The event was dated to the first of those three examinations. This is a repeatable, computer-based signal—not a guarantee that every flagged change represents irreversible glaucoma damage without any possible test or eye-health influence. () To look for a second event, the researchers reset the comparison: the first progressing visual field and the next examination became the new baseline tests. They then reapplied the same progression rule to the remaining tests. The recurrence analysis required at least four visual-field tests after the first progressing examination. () How often did progression recur? Across the full cohort, 1,951 of 7,457 eyes—26.2%—had an initial likely-progression event. Among the 635 eyes with enough subsequent testing and pressure data, 167—26.3%—had a recurrent event during the follow-up available to the study. () The researchers also used a time-to-event method that accounts for eyes having different lengths of follow-up. Its estimated cumulative recurrence was: For the full table, please open this article on visualfieldtest.com. At the 3-year mark, the 95% confidence interval was 11.6% to 17.1%; at 5 years, it was 22.1% to 29.5%; and at 10 years, it was 35.8% to 52.1%. The number at risk fell from 635 at the start to 30 at 10 years; it was 578 at 2 years, 382 at 4 years, 151 at 6 years, and 45 at 8 years. The 10-year estimate is therefore much less precise than the earlier estimates. () These numbers are not contradictory: 26.3% is the share of the 635 eyes with a recurrence recorded during their available follow-up. The 43.5% figure is the estimated cumulative chance by 10 years, accounting for differences in follow-up time. It does not mean that 43.5% of all 7,457 eyes recurred. The paper also notes that recurrence was recorded more often in the 635-eye analysis than in the broader group of eyes with initial progression—26.3% versus 15.2%—in part because eyes without enough later tests could not register a recurrence. () Which eyes were more likely to progress again? The strongest signal was how quickly the visual field had already been worsening. In the study’s adjusted analysis, each 1-decibel-per-year faster loss in mean deviation—a summary measure of visual-field damage—was associated with a 73% higher hazard of recurrence. “Hazard” describes the relative rate of a new event over time; it is not the same as an individual’s absolute probability of recurrence. () Other adjusted associations included: Higher average eye pressure after the first event: each additional 1 millimeter of mercury was associated with a 9% higher recurrence hazard. Greater pressure reduction: each additional 10% of reduction from the pre-event average was associated with an 11% lower hazard. The pressure level and percentage reduction were analyzed in separate models because they were related; they should not be added together as if they were independent effects. Older age: each additional five years was associated with roughly an 8% to 11% higher hazard, depending on the model. Visual-field damage at the first event: eyes with a less negative mean-deviation score—generally less advanced loss—had a higher measured recurrence hazard. The authors cautioned that progression can be harder to detect in advanced disease because damaged test locations have less remaining range to worsen. () The study’s combined prediction model had moderate, not high, ability to distinguish which eyes would recur. It is a useful risk signal, not a validated calculator for an individual patient. () Fast progressors stood out Among 96 eyes losing more than 1 decibel per year before the first event, 42.7% had recurrent progression, compared with 23.4% of slower-progressing eyes. The difference was about 19 percentage points. () This does not mean that every fast-progressing eye will worsen again, or that every slower-progressing eye is safe. It does mean that the earlier rate of change contains important information: a first progression event in an eye that was already losing field quickly deserves particular attention. What happened to fast-progressing eyes after the first event? The study compared the change in mean-deviation slope for fast-progressing eyes that did and did not have a recorded recurrence: Fast progressors without a recorded recurrence slowed from about −1.71 to −0.39 decibels per year after the first event. Fast progressors with recurrence slowed less, from about −1.70 to −1.31 decibels per year. The groups’ pre-event slopes were nearly identical. Afterward, the nonrecurrence group had a lower average pressure—14.0 versus 16.2 millimeters of mercury—and a pressure reduction greater than 20% was more common among them, 36.4% versus 12.2%. These are striking observations, but they do not establish why the groups’ courses diverged. () Does this show that stronger pressure lowering changed the disease course? It is consistent with that possibility, but it is not proof. Pressure lowering is already supported by randomized trials as a way to reduce glaucoma progression. In the Bascom Palmer study, recurrence was also associated with higher post-event pressure, and eyes with a larger pressure reduction tended to fare better. But the study did not randomly assign people to different pressure targets or treatment plans. () Several other explanations could contribute: Regression to the mean: an eye selected because it had a particularly steep prior decline or a triggering progression event may show a less extreme slope later, even without an effective treatment change. This is especially relevant when comparing a very fast pre-event period with the period afterward. Treatment-selection bias: clinicians may intensify treatment for eyes thought to be at greatest risk. In observational data, treatment and disease severity are intertwined, and the direction of the resulting bias is not predictable. Unknown treatment and adherence: the investigators did not have records of medication changes, laser treatment, surgery, or how consistently treatment was used. A lower recorded pressure could reflect any mix of treatment changes, improved adherence, or ordinary variation. Selection and follow-up: only 635 of the 1,951 eyes with initial progression had the post-event tests and pressure data needed for this analysis. Eyes that remain in care and receive more tests also have more opportunity for another event to be detected. Long-term estimates depend on assumptions about eyes that leave follow-up. () So the study supports a clinically plausible message—pressure reduction may help after progression is detected—but it does not show that a particular escalation caused the slowing seen in one subgroup. What does the pressure after the event tell us? The proportion of eyes with a recorded recurrence rose across the study’s categories of average post-event pressure: For the full table, please open this article on visualfieldtest.com. These are crude recurrence proportions by pressure category, not proof of a safe cutoff or a guarantee that a particular pressure prevents damage. The analysis found a graded association, but some eyes still progressed even when their recorded average was 12 millimeters of mercury o Support the show

    Once Glaucoma Starts Progressing, How Hard Is It to Stop? A New 12-Year Study Gives an Answer

  3. Oct 27

    Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/scientists-protected-glaucoma-nerve-cells-without-lowering-eye-pressure-could-mitochondria-become-the-next-treatment-target Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target? Short answer: possibly—but the new study is a promising prevention result, not yet proof that mitochondrial treatment can restore vision after glaucoma damage is established. The study at the center of this question was first published in Advanced Science on October 18, 2026. Researchers used adeno-associated virus serotype 2 to increase A-kinase anchoring protein 1, or AKAP1, in the retina. Treated mice retained more retinal ganglion cells, had better electrical responses, and showed stronger tracer labeling along the projection to the brain—even while their eye pressure remained elevated. The results support the idea of pressure-independent neuroprotection. They do not show that treatment lowered pressure, nor do they show that it rescued neurons after damage was already measurable. The October 2026 Advanced Science paper () That distinction matters. A treatment given before pressure injury may prevent cells from becoming dysfunctional or dying. A treatment given after visual function has declined would have to do something more: restore function in living but impaired cells, rebuild lost connections, or both. The study did not test that harder question. What AKAP1 does AKAP1 is a signaling scaffold, a protein that helps hold other signaling proteins in a useful place. It is normally attached to the outer membrane of mitochondria, the cell’s energy-producing structures. AKAP1 is not itself an energy-producing enzyme. Its importance is that it helps organize signals near the mitochondrion, where those signals can influence mitochondrial shape, stress responses, and survival. One important partner is protein kinase A, or PKA. AKAP1 can anchor PKA close to mitochondrial targets, including the fission protein DRP1. PKA-mediated phosphorylation of DRP1 at a particular site—serine 637 in the mouse numbering used in this work—usually makes DRP1 less able to drive mitochondrial fission. The calcium-sensitive enzyme calcineurin can remove that phosphate, which can favor DRP1 activity and mitochondrial division. Earlier laboratory work found that loss of AKAP1 in mouse retina was associated with lower DRP1 phosphorylation, more fragmented mitochondria, abnormal respiratory-chain proteins, and signs of oxidative and cell-death stress. The earlier retinal AKAP1 study () Mitochondria need both fusion and fission. Fusion can help mitochondria share contents and maintain function. Fission helps separate damaged parts, support mitochondrial transport, and allow quality-control processes such as mitophagy. The goal is not simply “more fusion.” It is a healthy balance that changes appropriately with a cell’s needs. AKAP1 is also linked to OPA1, a protein on the inner mitochondrial membrane that helps govern fusion and the structure of the folds called cristae. But the new study did not show that AKAP1 physically binds OPA1. It showed that OPA1 levels changed along with AKAP1 treatment. The direct mechanistic case is stronger for the AKAP1–PKA–DRP1 relationship than for any direct AKAP1–OPA1 interaction. Mitochondria also help manage cellular calcium and supply energy for processes such as nerve signaling and the release of neurotransmitters. It is therefore biologically plausible that mitochondrial stress could affect both calcium-sensitive signaling and synaptic performance. But in the new study, calcium handling was not directly measured, and the investigators did not establish that AKAP1’s synaptic effects were caused by restoring a particular calcium pathway. The authors themselves note that they did not measure PKA catalytic activity, recruitment of PKA to mitochondria, or formation of the AKAP1–PKA complex. () Is AKAP1 reduced in people with glaucoma? Not in the new October 2026 study: that study is based on mouse models and cultured retinal cells, not human donor retina. Its central experiments do not establish how AKAP1 changes in human glaucoma. There is, however, relevant human-tissue evidence in a separate study. In a small postmortem series, AKAP1 staining was lower within retinal ganglion-cell bodies from glaucoma donors. The overall retinal signal was not simply lower: AKAP1 staining was higher in some broader retinal measurements, apparently because AKAP1 was also increased in Müller glial cells. In other words, the answer depends on which cell type and which retinal region are measured. The human evidence is encouraging, but it is small, cross-sectional, and cannot tell whether the AKAP1 change caused degeneration or occurred in response to it. Related study including human donor retina () FACT: A separate small human-tissue study reports lower AKAP1 signal in glaucoma retinal ganglion-cell bodies. STRONG INFERENCE: AKAP1 may be relevant to human disease, but it is not yet established as a consistently reduced, causal driver across glaucoma patients. What the October 2026 study actually did The researchers used two mouse models and a set of cell-culture experiments. The treatment was a viral vector carrying mouse Akap1 under a broad cytomegalovirus promoter. The vector was not restricted to retinal ganglion cells; other retinal cells could also receive it. DBA/2J spontaneous glaucoma DBA/2J mice develop glaucoma as they age. The researchers injected the vector into the vitreous of 5-month-old mice and assessed them at 10 months. Age-matched DBA/2J-Gpnmb-positive mice, which do not develop the same glaucoma phenotype, served as non-glaucomatous controls. Only DBA/2J mice with recorded intraocular pressure between 20 and 35 millimeters of mercury were included in the glaucoma analyses. Across the screening cohort, 64 of 98 10-month-old DBA/2J mice had confirmed pressure elevation. The methods report peak-pressure averages of 21.5 ± 4.5 millimeters of mercury in right eyes and 19.9 ± 3.7 millimeters of mercury in left eyes for the glaucoma-mouse cohort; these are not presented as the treatment-versus-control means for the specific vector comparison. () The authors report that AKAP1-treated DBA/2J mice had: More retinal ganglion cells in both middle and peripheral retinal regions than glaucoma mice given the null vector. More cholera toxin B tracer labeling in the superior colliculus, a brain region receiving retinal input. Higher pattern electroretinogram and pattern visual evoked potential amplitudes. No improvement in pattern visual evoked potential latency. The vector increased retinal AKAP1 and also increased PKA abundance. The paper reports the main outcomes as statistically significant, but the searchable article text does not give exact group means or percentage improvements for the plots. The figure legends supply sample sizes: 20 mice per group for the pressure panel; 9–18 retinas or mice for retinal ganglion-cell counts; 10 mice per group for electrical responses; and three mice for the superior-colliculus tracer analysis. () Microbead-induced ocular hypertension In the second model, beads were placed in the front of the eye to obstruct fluid outflow and raise pressure. The article’s results section describes vector injection in 3-month-old mice, three weeks before the bead injection. The methods section, however, describes 6-week-old mice being injected with vector before bead administration. This age discrepancy is an internal reporting inconsistency. It does not change the key timing point: the vector was given before ocular hypertension was induced. The bead model produced sustained intraocular pressure in the reported range of 20–30 millimeters of mercury for at least eight weeks. Pressure monitoring did not show a statistically significant difference between AKAP1-vector and null-vector groups. Compared with null-vector mice, AKAP1-treated mice retained more retinal ganglion cells, had better pattern electroretinogram and pattern visual evoked potential amplitudes, and had shorter—more normalized—pattern visual evoked potential latency. The figure legend reports 12–14 mice per group for pressure monitoring and electrical responses, and 7–10 retinal wholemounts per group for retinal ganglion-cell counts. () The researchers also tested pressure-stressed retinal ganglion cells in culture. Cells were transduced with the vector before exposure to elevated hydrostatic pressure or paraquat, an oxidative stressor. AKAP1 improved cell viability and oxygen-consumption measures under stress. This is useful mechanistic support, but it is another pre-injury treatment experiment, not a rescue experiment. What the paper does—and does not—quantify The paper reports directions and statistical significance for many plotted outcomes, but the full-text prose and figure legends do not provide exact numerical means, standard deviations, or percentage changes for most of the outcomes listed below. I have not inferred precise bar heights from figures or invented values. For the full table, please open this article on visualfieldtest.com. The full study gives the sample sizes and qualitative results, but not an accessible numeric table of all plotted outcome values. That limits independe Support the show

    Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target?

  4. Oct 18

    Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/could-cataract-surgery-give-you-a-glaucoma-drug-that-lasts-for-years-the-bimatoprost-releasing-lens-explained Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained Potentially—but not for everyone, and not as a cure for glaucoma. SpyGlass Pharma’s investigational Bimatoprost Drug Pad–Intraocular Lens System, or BIM-IOL, combines an artificial cataract lens with two small drug-releasing pads. The lens is designed to release bimatoprost, a pressure-lowering medicine, for about three years. The early results are striking: in a randomized trial, roughly 96% to 98% of evaluable patients who received the drug-releasing lens were not using additional pressure-lowering drops at 12 months. A much smaller first-in-human study found that 20 of 21 participants followed for three years remained drop-free. Those results make the idea worth taking seriously. But “drop-free” is not the same as “glaucoma-free,” and the strongest three-year result comes from a small, uncontrolled study—not the larger randomized trial. This article reviews the evidence available as of October 18, 2026, including the latest American Academy of Ophthalmology meeting presentation. The BIM-IOL remains investigational and not approved by the United States Food and Drug Administration. AAO 2026 results coverage () What Is the SpyGlass Bimatoprost Drug Pad–Intraocular Lens? During cataract surgery, the cloudy natural lens is removed and replaced with an intraocular lens. The SpyGlass system uses a monofocal artificial lens with two bimatoprost-containing pads attached near the junction between the lens’s clear center and its supporting arms. The lens and pads are placed inside the eye’s capsular bag, where the natural lens used to sit. The pads are positioned outside the main visual area and are designed to release bimatoprost slowly. Unlike an implant placed in the eye’s drainage angle, the BIM-IOL is intended to leave that angle available for future glaucoma procedures. Adding the pads requires preparation of the lens but is intended to fit within a routine cataract-surgery workflow. Published three-year pilot study () The system is designed to deliver medication for three years. That is a design goal supported by laboratory release testing and early human pressure measurements—not yet proof that every patient will receive three full years of effective treatment. What Did the AAO 2026 Presentation Report? At the American Academy of Ophthalmology annual meeting in New Orleans, held October 9–12, 2026, investigator Fiaz Zaman presented 12-month results from SpyGlass’s randomized Phase 1/2 trial. The trial enrolled people with a cataract and either mild-to-moderate open-angle glaucoma or ocular hypertension. AAO 2026 presentation coverage () Trial groups and pressure results A total of 104 people were randomized: For the full table, please open this article on visualfieldtest.com. All participants stopped their existing pressure-lowering treatment for a washout period before the baseline measurements. The exact group mean washout pressures were not included in the public AAO report I could verify. Dividing the reported pressure reductions by the rounded percentages gives an approximate baseline of about 25–27 mmHg, depending on group and measurement time. These are calculated estimates, not separately published baseline figures. AAO 2026 results report () The lower-dose group had a numerically larger reduction than the higher-dose group. That does not establish that 39 micrograms is better: these reported averages do not demonstrate a clear dose-response relationship, and the small groups are not a definitive dose comparison. How many patients were off pressure-lowering drops? At 12 months, the presentation reported that: 98% of patients in the 78-microgram group were off additional pressure-lowering medication. 96% of patients in the 39-microgram group were off additional pressure-lowering medication. Control-group participants were not reported as drop-free in the same sense: they were still using their assigned twice-daily timolol. The company has summarized the combined treated groups as approximately 97% off topical pressure-lowering therapy at 12 months. “Medication-free” here means free of additional pressure-lowering eye drops; patients in the BIM-IOL groups used artificial tears as part of the trial and still received ordinary postoperative eye care. AAO 2026 report and SpyGlass Phase 1/2 results () Vision, corneal cells, and adverse events The reported visual outcomes were reassuring: All evaluable eyes in all three groups achieved best-corrected distance vision of 20/32 or better. Vision of 20/20 or better was reported in 74% of the 78-microgram group, 65% of the 39-microgram group, and 63% of the control group. Average vision across groups was about 86 letters, roughly equivalent to 20/20 vision. The presentation also reported corneal endothelial cell density, a measure of the health of the cells lining the inside of the cornea: For the full table, please open this article on visualfieldtest.com. The investigators characterized the overall safety profile and endothelial-cell loss as comparable to routine cataract surgery. However, the numerically larger decline in the smaller 39-microgram group deserves follow-up. These are calculations from reported group averages; the public conference coverage does not provide a full adjusted comparison or enough detail to interpret the differences confidently. AAO 2026 safety and vision results () Any adverse event was reported in 21 people in the 78-microgram group (41%), 10 in the 39-microgram group (43%), and 11 in the control group (37%). The report described no serious adverse events, secondary surgical interventions, or lens explantations through 12 months. The public report does not provide a complete event-by-event breakdown, so the overall percentages should not be read as the proportion who had a problem caused by the drug pads. () How Meaningful Is a 96–98% Drop-Free Result? It is a meaningful early signal. If confirmed in larger and longer studies, avoiding daily pressure-lowering drops could reduce the burden of remembering, handling, and paying for them. That could matter especially for people who struggle with daily dosing. But the headline needs context. It does not mean 98% of patients stopped drops they were taking About one-third of trial participants were taking no pressure-lowering medication at screening. They may have had elevated pressure without current treatment, or they may have been suitable for observation under their clinicians’ care. So the reported drop-free percentage is not the same as saying that 96–98% of people who had been using drops successfully stopped them after surgery. The report does not provide enough detail to calculate that specific number. AAO 2026 study details () The control group also had a large pressure reduction The control group had ordinary cataract surgery, received a standard lens, and used timolol. Its reported pressure reduction—about 35% at 12 months—was close to the reductions in the drug-pad groups. This trial therefore supports the idea that the BIM-IOL can maintain pressure control while avoiding assigned timolol drops; it does not show that the BIM-IOL lowered pressure more than the control treatment. Cataract surgery itself can lower pressure, especially when the starting pressure is high. Estimates differ depending on the patients studied and whether pressure-lowering medications were stopped before measurement. A 2024 review of cataract-surgery trials found a 12-month average reduction of about 3.8 mmHg overall, with a larger average reduction in studies that used a medication washout. Cataract-surgery meta-analysis () “Drop-free” is not the same as “glaucoma controlled for life” The Phase 1/2 trial reported eye pressure, vision, medication use, and safety. It did not establish that the lens prevents future visual-field loss, stops optic-nerve damage, or removes the need for future glaucoma care. The 12-month results are also interim data presented at a medical meeting; the available report is not a full peer-reviewed paper with all trial details. Bottom line: the result is promising evidence of a strong chance of being free from additional pressure-lowering drops at one year in this selected study group. It is not yet proof that most people having cataract surgery can avoid glaucoma treatment indefinitely. Does the Pressure-Lowering Effect Really Last Three Years? The most direct human evidence comes from a small, prospective, nonrandomized first-in-human study in Honduras. The published paper says 24 people consented; company materials have described 23 people assigned to dose groups. Twenty-one were followed through 36 months. The study tested older configurations containing 75, 150, or 300 micrograms of bimatoprost—not the 39- and 78-microgram doses in the later randomized trial. Published three-year pilot study and company 36-month results () At 36 months, the reported average pressure for evaluable participants had fallen from 25.1 ± 2.5 mmHg after washout to 15.9 ± 2.7 mmHg, a reduction of about 37%. Twenty of 21 participants were still free of topical pressure-lowering medication. All 21 had at le Support the show

    Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained

  5. Oct 17

    Do Alcohol and Smoking Increase Glaucoma Risk? A New 9,418-Person Study Finds a Stronger Link

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/do-alcohol-and-smoking-increase-glaucoma-risk-a-new-9-418-person-study-finds-a-stronger-link Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Do Alcohol and Smoking Increase Glaucoma Risk? A New 9,418-Person Study Finds a Stronger Link A study published on October 10, 2026, reports that alcohol use and cigarette smoking were more common among people with primary open-angle glaucoma in a large African clinic-based sample. The headline figures are striking: former drinkers had about 49% higher odds of glaucoma, and current smokers about 46% higher odds. But the details complicate the headline. This was a cross-sectional, clinic-based study, not a study that followed healthy people to see who later developed glaucoma. Most cases came from glaucoma clinics, while most controls came from cataract or general medical clinics. The researchers measured recent substance use, not lifetime exposure. And when former drinkers were excluded, the association between current drinking and glaucoma was no longer statistically clear. My overall reading: heavy or repeated binge drinking may modestly contribute to glaucoma risk, but the evidence is not conclusive. The case that cigarette smoking causes glaucoma to develop is weaker. Smoking may, however, speed up structural damage in people who already have glaucoma; that possibility has some direct but limited evidence. The new Eyes of Africa study: what it found The Eyes of Africa analysis included 9,418 people aged 40 or older: 5,189 with primary open-angle glaucoma and 4,229 controls. Participants were enrolled from 2017 through 2023 at 16 centers in Nigeria, Ghana, and Malawi. The researchers used structured interviews to ask about alcohol, tobacco, medications, and other substances, then used statistical models to estimate adjusted odds of being a glaucoma case. The Eyes of Africa alcohol-and-smoking study How cases and controls were recruited The sample was assembled mainly through eye-care clinics, rather than by randomly sampling the population: 98.6% of glaucoma cases came from glaucoma clinics; 1.4% came from community outreach. 93.1% of controls came from cataract clinics or general geriatric clinics; 6.9% came from community outreach. The teams invited consecutive eligible patients, which helps avoid cherry-picking within those clinics—but does not make the clinics representative of the wider population. That imbalance matters. It means the study’s odds ratios describe differences in this selected case-control sample; they are not direct estimates of how much an individual’s chance of developing glaucoma changes. Eyes of Africa study methods How glaucoma was diagnosed The study used the International Society of Geographical and Epidemiological Ophthalmology criteria. In everyday terms, a diagnosis required evidence of damage to the optic nerve, usually supported by a characteristic visual-field defect, an open drainage angle on gonioscopy, and no other eye condition that better explained the damage. In some severely damaged eyes where a usable visual-field test was not possible, advanced optic-nerve damage could support the diagnosis. Controls had no clinical evidence of glaucoma and an eye pressure below 22 millimeters of mercury. Eyes of Africa methods The substance-use article itself does not report glaucoma severity or eye pressure by alcohol or smoking category. A companion report on the same cohort supplies useful context: cases averaged 63.9 years of age versus 61.4 for controls; 76.8% of cases had severe glaucoma in at least one eye at recruitment. Average eye pressure at study entry was 19.8 millimeters of mercury in cases, compared with 14.5 in hospital-based controls and 12.8 in community controls. The cases’ average historical maximum pressure was 24.9. These figures describe the overall cohort—not the drinking or smoking subgroups—and many cases were already receiving treatment. Eyes of Africa cohort profile Age and social differences between groups The glaucoma group was older. Among cases, 29.1% were 80 or older, compared with 21.7% of controls. Cases were also more often male, unemployed, and had completed secondary education or more. In the adjusted model, unemployment was associated with higher odds of being a case (1.23), as was secondary education or higher (1.27). These are social characteristics, not proof that unemployment or education causes glaucoma; they may also reflect differences in health, access to eye care, or diagnosis. Eyes of Africa study results The reported alcohol and smoking figures The study’s adjusted odds ratios, compared with never-users unless otherwise specified, were: For the full table, please open this article on visualfieldtest.com. The reported estimates are real, but they need careful interpretation. “Former drinker” meant no alcohol in the 30 days before the interview, not necessarily someone who had permanently quit after years of heavy drinking. “Current drinker” meant at least one drink in that 30-day period. “Former smoker” meant having smoked more than 100 cigarettes over a lifetime but not in the prior 30 days. These brief definitions do not tell us how much a person used to drink or smoke, for how long, or how long ago they stopped. Eyes of Africa exposure definitions and regression results There is also an important detail about the “heavy episodic drinking” result. In the paper, the measure was the largest amount ever consumed in a single day: more than two drinks versus two or fewer. It did not measure how often this happened or the person’s lifetime total. It is therefore not a reliable measure of sustained heavy drinking, and it is not the same as a well-characterized dose-response analysis. What the study did—and did not—show about dose The study did not record lifetime alcohol units or smoking pack-years. Pack-years combine the number of cigarette packs smoked each day with the number of years smoked. Without these cumulative measures, the researchers could not test whether risk rose steadily with long-term exposure. Among current drinkers, reported monthly consumption did not differ significantly between cases and controls. Among current smokers, the number of cigarettes smoked per day also did not differ significantly. Those comparisons were limited by small numbers at higher exposure levels. The study therefore offers no clear dose-and-frequency curve for either substance. Eyes of Africa alcohol and tobacco patterns Two further results deserve attention: In an analysis restricted to current and never-users, current drinking was not associated with higher glaucoma odds: adjusted odds ratio 0.90 (95% confidence interval 0.78–1.04). The alcohol signal in the main analysis was therefore substantially influenced by the former-drinker group. In that restricted analysis, the association with current smoking remained: adjusted odds ratio 1.62 (95% confidence interval 1.16–2.27). This is still an association within a clinic-based sample, not proof of causation. The team adjusted for age, sex, education, employment, country of birth, and other measured substance-use variables. It did not fully account in its main model for factors such as family history of glaucoma, eye pressure, central corneal thickness, myopia, or a detailed set of medical and vascular conditions. A supplementary model adding body mass index reduced the current-alcohol association until it was no longer statistically significant; the authors reported that several other associations changed less. Eyes of Africa adjusted results and limitations Why do former drinkers look worse than current drinkers? At first glance, the former-drinker result—an odds ratio of 1.49, compared with 1.15 for current drinkers—could seem to suggest that quitting alcohol increases glaucoma risk. That is not a sensible causal interpretation. Several other explanations are more likely. Illness-related quitting and reverse causation People may reduce or stop drinking after a diagnosis, after developing another illness, or when treatment or family circumstances change. If some glaucoma cases had already been diagnosed before the interview, their diagnosis could have influenced their drinking. Because glaucoma often develops unnoticed for years, it is difficult to know whether alcohol use preceded the disease, changed because of it, or both. The Eyes of Africa study does not report when each person stopped drinking relative to glaucoma onset or diagnosis. Its cross-sectional design cannot sort out that sequence. The researchers themselves noted that people may have reduced drinking after diagnosis or health advice. Eyes of Africa discussion The “former drinker” category combines very different people A person who stopped drinking last week and a person who stopped decades ago are both “former drinkers” in this analysis. So are people who drank only occasionally and happened not to drink in the last 30 days. The category does not distinguish illness-related quitting from social, religious, financial, or other reasons for not drinking. This broad grouping can make the former-drinker association difficult to interpret. It also leaves room for sick-quitter bias: people may quit because they are unwell, and their illness—not their quitting—may be associated with glaucoma or with clinic attendance. Age, health, and survival could also contribute Cases were older than Support the show

    Do Alcohol and Smoking Increase Glaucoma Risk? A New 9,418-Person Study Finds a Stronger Link

  6. Oct 16

    A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-procedure-uses-donor-tissue-to-keep-the-eye-s-drainage-canal-open-first-human-results-are-in Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In Short answer: The first results are encouraging, but they do not yet show that donor tissue makes canaloplasty more durable. The reported 52-eye study has no published full paper, no control group, and only six months of follow-up. Because the procedure was combined with cataract surgery, some—and possibly a substantial part—of the pressure drop may have come from cataract removal rather than the allograft. The idea is plausible: open Schlemm’s canal, then support it with donor tissue. But the key claim—that this support prevents clinically important canal recoil and improves lasting pressure control—still needs a randomized comparison. Evidence reviewed through October 16, 2026. What the first 52-eye results show On October 8, 2026, Iantrek announced preliminary six-month results from a first-in-human, single-center observational study of bio-reinforced canaloplasty combined with cataract surgery. The company reported outcomes for 52 treated eyes. The full study report was not published with the announcement; the data were described as “on file” and subject to further analysis. (Iantrek’s October 8 announcement, Ophthalmology Management’s report) For the full table, please open this article on visualfieldtest.com. The 14.1 figure is calculated, not separately published: 22.4 × (1 − 0.372) = 14.07. Because the baseline and percentage are rounded, the exact study mean might differ slightly. The medication calculation is also approximate: a 49.1% reduction from 1.2 medications implies a reduction of about 0.59, leaving an average of about 0.61. These are the figures in the company announcement, not independently audited results. “No serious adverse events” does not mean there were no minor events, and a group of 52 eyes followed for six months cannot rule out uncommon complications or late problems. Important study details are not yet public The announcement does not provide enough information to establish several facts requested for a proper clinical assessment: Glaucoma severity and subtype: Not reported for the 52-eye cohort. Patient age: Not reported. Previous selective laser trabeculoplasty or minimally invasive glaucoma surgery: Not reported. Detailed inclusion criteria: Not reported. Medication washout before baseline pressure measurement: Not reported. This matters: a pressure measured after stopping drops is not directly comparable with one measured while patients are taking them. Cataract surgery: The study is described as bio-reinforced canaloplasty performed with cataract surgery. That implies the reported 52 eyes had combined surgery, but the press release does not provide a patient-by-patient study table. Exact surgical steps: The type of dilation, how much of the canal was treated, and the precise graft-placement steps are not reported. Allograft length and exact placement extent: Not reported for AlloSpan. Postoperative eye-drop regimen: Not reported. A separate, ongoing study called BOOST is registered as an observational study of bio-reinforced canaloplasty. Its registry describes placing minimally manipulated, homologous-use scleral allograft tissue in the wall region of Schlemm’s canal after canaloplasty. It targets 300 participants and plans two years of follow-up; it is not a randomized comparison of graft versus no graft. BOOST’s eligibility rules should not be assumed to describe the earlier 52-eye study. (BOOST study record) What “bio-reinforced canaloplasty” means The eye continuously produces clear fluid called aqueous humor. It normally drains through the trabecular meshwork, into Schlemm’s canal, and then through collector channels toward the veins around the eye. In open-angle glaucoma, pressure can rise when this drainage system does not carry fluid away efficiently. Conventional canaloplasty In conventional canaloplasty, a surgeon uses an instrument to enter and dilate Schlemm’s canal, commonly by delivering a viscoelastic fluid. Some versions also place a tensioning suture around the canal; other, newer ab-interno procedures do not. The goal is to stretch the canal and improve flow through the eye’s existing drainage route. The proposed AlloSpan approach Bio-reinforced canaloplasty adds another step: after dilating the canal, the surgeon places homologous donor scleral tissue in the canal-wall region to provide structural support. Public descriptions also characterize the platform as nitinol-guided and trabecular-meshwork-sparing, but the detailed steps used in the 52-eye study have not been published. (BOOST study record, Iantrek’s AlloSpan introduction) The concept is therefore: Conventional approach: Dilate the canal; hope the improved opening and flow persist. Bio-reinforced approach: Dilate the canal, then add a biological scaffold intended to support its structure. The word “reinforced” describes the intended mechanical role. It does not yet establish that the canal stays wider, that collector-channel flow improves, or that pressure control lasts longer. Does Schlemm’s canal actually collapse or recoil after canaloplasty? Canal narrowing is a real feature of eye anatomy. But current evidence does not establish that post-surgical recoil is a major cause of conventional canaloplasty losing effectiveness. What imaging and tissue studies show Anterior-segment optical coherence tomography studies have found that Schlemm’s canal can be larger after canaloplasty. One study documented increased canal dimensions during the first few months after surgery; another examined canal and trabecular-meshwork changes one year after combined cataract surgery and canaloplasty. Those studies support the idea that surgery changes the canal’s anatomy. They do not show that later pressure rises are caused by canal recoil, or that a graft prevents such rises. (Three-month imaging study, one-year phacocanaloplasty imaging study) Laboratory and histological work also shows that the trabecular meshwork can bow toward—and narrow—the canal as pressure changes. But Schlemm’s canal is not simply an empty pipe. Its walls, internal supports, collector-channel openings, and surrounding tissues all respond to pressure. (Histopathological review of trabecular surgery, study of Schlemm’s canal and collector-channel anatomy) Conventional canaloplasty can last for years without an allograft Longer-term clinical results show that conventional canaloplasty can retain meaningful effects, although the evidence is mostly nonrandomized and outcomes vary. In a multicenter three-year study, the overall mean pressure was 15.2, while eyes having combined cataract surgery and canaloplasty averaged 13.6. In a separate ten-year observational study, mean pressure at ten years was 15.9 after canaloplasty alone and 14.2 after combined cataract surgery and canaloplasty. Medication use rose over time in some groups, suggesting that pressure lowering and medication reduction are not the same thing. (Three-year canaloplasty results, ten-year canaloplasty results) These studies do not prove that canal anatomy never changes after surgery. They do show that a donor scaffold is not already known to be necessary for long-term canaloplasty benefit. A key missing link is evidence that patients whose canal later narrows are the same patients whose pressure control fails. A larger canal may not solve all drainage problems Even with a wider canal, fluid must still pass through the collector channels and other downstream tissues. Research suggests a substantial share of resistance can lie beyond Schlemm’s canal, in the collector-channel and venous pathways. So keeping the canal open could help, but it cannot necessarily fix blocked or poorly functioning downstream drainage. (Review of Schlemm’s canal procedures and outflow resistance) How much of the pressure drop could cataract surgery explain? This is the study’s biggest interpretive problem. AlloSpan was not tested against cataract surgery alone or against ordinary canaloplasty. Cataract removal can lower pressure on its own, especially when the pressure before surgery is high. In the randomized HORIZON trial, patients with open-angle glaucoma had a medication-washout baseline mean pressure of about 24.5. At 24 months, the cataract-surgery-only group had an average pressure decrease of 5.3, about 22% of baseline. In an Ocular Hypertension Treatment Study analysis, cataract surgery was associated with a pressure decrease from a higher baseline, but the effect differed according to baseline pressure and medication use. (HORIZON trial report, Ocular Hypertension Treatment Study cataract analysis, analysis of cataract surgery in treated patients) The AlloSpan announcement implies an overall decrease of about 8.3—from 22.4 to about 14.1. As a rough comparison: If the 22.4 baseline was measured after medication washout, cataract-only results in a similar pressure range suggest cataract surgery might explain around 5 millimeters of mercury, or about 22 percentage points of the reported reduction. If baseline was measured while patients were using their usual drops, the cataract-only contribution might be closer Support the show

    A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In

  7. Oct 15

    Can One Tiny Glaucoma Implant Replace Years of Eye Drops? New Randomized iDose TR Results

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/can-one-tiny-glaucoma-implant-replace-years-of-eye-drops-new-randomized-idose-tr-results Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Can One Tiny Glaucoma Implant Replace Years of Eye Drops? New Randomized iDose TR Results A small randomized trial reported a sizeable pressure reduction when iDose TR was added to cataract surgery: at three months, the combination group’s average daytime eye pressure fell by 11.1 millimeters of mercury, compared with 7.4 millimeters after cataract surgery alone. The company-reported difference between groups was 3.6 millimeters of mercury. That comparison is the key result: because both groups had cataract surgery, it estimates the extra short-term reduction associated with adding iDose TR in this trial setting. But the public results are only a topline report. They do not provide the starting pressures, final average pressures, confidence intervals, responder percentages, or enough detail to separate the effect of cataract surgery from medication washout and other baseline changes. Nor do they show whether the additional reduction lasts one or three years. Bottom line: iDose TR may reduce the need for daily drops for some people. The new trial supports an additional pressure-lowering effect at three months, but it does not yet show that an implant every few years can replace all drops—or postpone laser or glaucoma surgery over the long term. The Phase 4 results were announced on October 9, 2026. As of October 15, 2026, the results were available as a company-released topline report, not a full peer-reviewed publication. (Glaukos/Business Wire release) () What GLK-101-04 tested GLK-101-04 was a Phase 4 trial comparing iDose TR implanted during cataract surgery with cataract surgery alone. The official trial registry number is NCT06848946. (ClinicalTrials.gov record) () For the full table, please open this article on visualfieldtest.com. The public registry gives only a limited account of eligibility. It lists active corneal inflammation or swelling and certain retinal disorders as exclusions. It does not report the trial’s glaucoma-severity distribution, baseline visual-field damage, or the prior laser and surgery history of the participants in the topline announcement. (ClinicalTrials.gov record) () What is not public yet The topline release and registry do not provide the following information for GLK-101-04: Medicated starting pressure and unmedicated starting pressure. Whether pressure-lowering medicines were washed out before baseline, and, if so, how. How many participants used one or more glaucoma medicines before the trial. Detailed prior treatment history, such as selective laser trabeculoplasty or earlier glaucoma surgery. How many participants had mild, moderate, or advanced glaucoma. The group’s final average pressure at Month 3. Exact responder rates at reductions of 20%, 30%, or 40%. The percentages reaching pressure thresholds of 18, 15, 12, or 10 millimeters of mercury. The treatment difference’s confidence interval or standard deviation. A related earlier study of iDose TR used pressure-lowering medicine washout, but that does not establish that GLK-101-04 used the same rules. The new trial’s own public information is insufficient to confirm washout or reconstruct its baseline pressure. (Earlier iDose TR phase 3 report) () What the three-month results do—and do not—tell us The company reported mean daytime pressure reductions from baseline of: 11.1 millimeters of mercury with iDose TR plus cataract surgery. 7.4 millimeters of mercury with cataract surgery alone. A reported incremental treatment effect of 3.6 millimeters of mercury, with p0.0001. The release says iDose TR was statistically superior across all prespecified secondary responder analyses, but it does not publish the responder thresholds or the percentage of eyes meeting them. (Glaukos/Business Wire release) () Can we calculate final pressures or percentage reductions? No—not from the public numbers. A pressure reduction is not the same thing as a final pressure. If a group’s starting mean pressure were known, its final mean could be estimated by subtracting the reported reduction. But GLK-101-04’s starting group means have not been reported. For the same reason, the percentage reduction cannot be calculated. It requires both the absolute decrease and the starting pressure. The company’s reported 3.6 millimeters of mercury is an absolute between-group difference, not a percentage reduction. The release’s rounded reductions, 11.1 and 7.4, subtract to 3.7, while the company reports an incremental difference of 3.6. This small mismatch can arise when a treatment difference is calculated from unrounded statistical estimates and the displayed group changes are rounded. The release does not provide the unrounded values or analysis details needed to resolve it. Effect size and confidence intervals The reported 3.6 millimeters of mercury is the available absolute treatment effect. Relative to the 7.4-millimeter reduction reported in the surgery-alone group, it is about 49% larger. That is a descriptive comparison—not a standardized effect size, and not proof that the implant is 49% more effective than cataract surgery in general. The release does not provide a confidence interval, standard deviation, or standard error. Therefore, neither a confidence interval nor a standardized effect size can be calculated responsibly from the public topline data. The reported p0.0001 indicates strong statistical evidence of a difference under the trial’s analysis, but it does not supply those missing quantities. How much came from medication washout, surgery, and iDose TR? The best-supported answer is: iDose TR’s added effect: The randomized comparison suggests about 3.6 millimeters of mercury more reduction at Month 3 in the iDose-plus-surgery group than in the surgery-alone group. Cataract surgery and other shared influences: The 7.4-millimeter reduction in the control group occurred after cataract surgery, but it cannot be assigned to surgery alone. Medication washout and baseline effects: Their contribution cannot be determined because the public report does not disclose whether washout occurred or when baseline was measured in relation to medication use. The 7.4-millimeter control-group decrease could reflect cataract surgery plus baseline conditions, medication changes, and other influences. A trial without a no-surgery group cannot isolate cataract surgery from all other changes. Research on cataract surgery alone in open-angle glaucoma has found a smaller average pressure reduction at 12 months in many studies, although results vary with starting pressure, use of medication washout, and study design. Those findings are useful context, but they cannot be used to reassign the components of GLK-101-04’s 7.4-millimeter change. (2024 systematic review; systematic review of cataract surgery and glaucoma) () Interpretation: the 3.6-millimeter between-group difference is the most relevant estimate of iDose TR’s added short-term effect in this trial. The full 11.1-millimeter reduction should not be described as the implant’s effect alone. Why an extra 3–4 millimeters of pressure reduction can matter Glaucoma damages the optic nerve and can cause permanent vision loss. Lowering eye pressure is the main proven way to slow that damage, but the pressure target must be chosen for the individual eye. A pressure that is adequate for one person may be too high for someone with more damage or faster progression. In the Early Manifest Glaucoma Trial, each millimeter of mercury of lower pressure during follow-up was associated with roughly a 10% lower risk of progression. If that relationship were simply extended to a sustained 3–4-millimeter reduction, it would suggest a potentially meaningful reduction in relative risk. But that is a model-based extrapolation, not a finding that iDose TR itself has reduced visual-field progression by a specific percentage. The trial tested pressure at three months, not years of vision outcomes. (Early Manifest Glaucoma Trial analysis) () The Collaborative Normal-Tension Glaucoma Study also found less progression in treated eyes targeted for a 30% pressure reduction than in untreated eyes. That study involved a selected group of people with normal-tension glaucoma who already had documented progression or other high-risk features; its results cannot be applied mechanically to every person with glaucoma or ocular hypertension. (Collaborative Normal-Tension Glaucoma Study) () What it might mean for different pressure targets These are clinical illustrations, not predictions of the final pressures in GLK-101-04. The trial has not reported the absolute starting or final group means, and an average group difference does not predict each individual’s response. For the full table, please open this article on visualfieldtest.com. The American Academy of Ophthalmology describes an initial treatment goal of reducing pressure by about 20% to 30% for many patients with primary open-angle glaucoma, then adjusting the goal for disease severity and response. A target is not a universal threshold, and a three-month pressure result does not replace ongoing checks of optic-nerve health and visual fields. (American Academy of Ophthalmology Preferred Practice Pattern) () How iDose TR compares with other trea Support the show

    Can One Tiny Glaucoma Implant Replace Years of Eye Drops? New Randomized iDose TR Results

  8. Oct 12

    First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/first-human-er-100-results-did-epigenetic-reprogramming-actually-restore-some-vision-in-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma? Evidence cutoff: October 12, 2026. Bottom line Life Biosciences has reported an intriguing first human visual-field signal, but it has not shown that ER-100 restored lost vision. The company says that two of three people with open-angle glaucoma had more than a 4-decibel improvement at at least 28% of visual-field test locations at Day 56. On the registered test pattern, that is about 15 locations. That is worth investigating. But the public report does not include the patients’ visual-field charts, their baseline measurements, repeat-test confirmation, global visual-field scores, or results from the untreated eyes. It also does not establish that the improvement occurred in previously damaged areas or that it reflects retinal ganglion-cell recovery rather than visual-field variability, learning, or another measurement effect. ER-100 may be the first reported human signal for this partial-reprogramming approach. It is not the first human suggestion that some glaucomatous visual dysfunction can improve: earlier studies have reported improved retinal or visual-field measures after pressure reduction and other interventions. Nor do the three ER-100 cases establish that this particular treatment reversed damage. For the full table, please open this article on visualfieldtest.com. The main clinical facts come from Life Biosciences’ October 8 announcement and the trial registry. The company’s release reports the visual-field threshold; the registry describes the trial’s design and planned measurements. () What was actually disclosed Treatment and follow-up The October 8, 2026 announcement concerned three participants with open-angle glaucoma who received one intravitreal injection of ER-100 at Dose Level 1: 2 × 10¹¹ vector genomes in one eye. They took daily oral doxycycline for 56 days to induce expression of OCT4, SOX2, and KLF4, known together as OSK. The company also reported an oral prednisolone taper intended to reduce inflammation related to the adeno-associated virus type 2 vector. It did not disclose the steroid dose or taper schedule in the release. () The company said that visual-field improvement was observed in two of the three participants at Day 56. In both, at least 28% of visual-field locations showed an improvement of more than 4 decibels. The Data Safety Monitoring Board recommended moving to Dose Level 2, 6 × 10¹¹ vector genomes—three times the first dose. () The trial is open-label, non-randomized, and primarily designed to evaluate safety and tolerability. Its registry describes sequential dose escalation in glaucoma, followed by a separate cohort with non-arteritic anterior ischemic optic neuropathy. The full study is planned to follow participants for as long as five years. () What I could verify about the presentation and reporting Life Biosciences announced that it would present the results at Eyecelerator during the American Academy of Ophthalmology meeting. The event listing confirms the October 8 Eyecelerator program. As of October 12, the material I could verify that gives detailed human results is the company’s release; I could not locate a publicly accessible patient-level slide deck, visual-field printouts, presentation transcript, or detailed independent conference account. Available news summaries largely repeat the company’s reported numbers rather than adding patient-level data. () That distinction matters: the reported threshold is a company-reported observation, not a publicly inspectable result that outside clinicians can reanalyze. What is—and is not—known about the three participants The trial registry supplies eligibility limits. It does not provide the first three participants’ individual clinical records. The company has not released a patient-by-patient table. For the full table, please open this article on visualfieldtest.com. For the glaucoma cohort, the registry defines eligible visual-field loss as mean deviation from −6 to −20 decibels and an eligible eye-pressure value below 30 millimeters of mercury. These limits should not be mistaken for the actual values of the three treated participants. () What does “28% of points improved by more than 4 decibels” mean? About 15 locations—not 28% of vision restored The 24-2 visual-field pattern tests points across the central visual field. Depending on whether the blind-spot locations are counted in the denominator, the conventional point count is 52 or 54. Twenty-eight percent of either count is about 15 locations. This does not mean that 28% of lost vision came back. A visual-field test records sensitivity at discrete locations; the company did not report how large the average improvement was, how much each location had been damaged, or what happened at the remaining locations. A change greater than 4 decibels at a previously impaired location could be important if it is repeatable. But a list of points crossing a threshold is not the same as an overall improvement in the visual field. Improvements in some locations can coexist with worsening or unchanged sensitivity elsewhere. The registry identifies change in overall mean deviation as a visual-field measure; the announcement instead highlights the percentage of locations crossing the 4-decibel threshold. Neither the maps nor the global scores were released. () The crucial unanswered questions The public disclosure does not show: whether the improved locations formed a coherent cluster or were scattered; whether those locations matched previously damaged areas; whether the same locations improved on a second or third post-treatment test; whether other locations worsened enough to offset the gains; changes in mean deviation, visual field index, or pattern standard deviation; whether the untreated fellow eye changed similarly. Those details would help distinguish a plausible recovery pattern from a noisy or broadly shifted test result. How often can a visual-field point improve by more than 4 decibels by chance? Variability is greatest in damaged regions A visual-field result is not a perfectly stable reading of nerve function. The pointwise test-retest variability differs by location and by the amount of existing damage. In a study of glaucoma patients tested repeatedly, sensitivity at locations with moderate loss sometimes ranged from a near-normal result to an absolute defect across tests. Other work finds greater variability at lower sensitivities, with a measurement floor affecting very advanced damage. () A large study of 4,044 glaucoma eyes found substantial overall test-retest variation, and found that test results at central locations tended to be more correlated across tests than those at peripheral locations. That overall measure is not a point-specific probability that a 4-decibel improvement will happen, but it reinforces why a one-time change needs context. () For a rough illustration—not a patient-specific estimate—if a damaged location has a paired test-to-retest difference standard deviation of 3 decibels, a one-sided improvement greater than 4 decibels would occur about 9% of the time under a simple bell-curve model. If that standard deviation is 6 decibels, the estimate is about 25%. At a relatively healthy location, variability is much lower, so a 4-decibel gain is much less likely. Published descriptions of perimetric variability support a wide range, rather than one universal probability for every point. () Why 15 points cannot be treated as 15 independent coin flips Visual-field locations are not independent. A participant’s alertness, fatigue, fixation, test comprehension, and general performance can influence many locations in the same session. Learning can also improve results across a field. Those shared influences make a cluster of improved points more likely than a calculation that assumes every point fluctuates independently. To show how much the answer depends on assumptions, consider an illustrative correlated-error model for 52 locations. Suppose each location has a 10% chance of improving by more than 4 decibels from measurement variation alone. If locations were independent, the chance of at least 15 improvements would be about 0.04%. With modest positive correlation among locations, a rough overdispersed model puts it in the low single digits, rather than near zero. If the individual-location chance were 20%, the corresponding estimate could range from roughly 8% under independence to about 15–30% under illustrative positive-correlation assumptions. These are sensitivity calculations, not estimates of what happened to these participants. They assume a simplified common degree of pointwise variability and correlation; actual fields mix normal, moderately damaged, and severely damaged locations. The true chance for any of the three participants cannot be calculated without their baseline and repeat fields, test reliability values, and pointwise error structure. Still, the exercise shows why “15 points” is not automatically extraordinary—and why the raw maps and repeated tests are essential. Learning, regression to the mean, and test quality In one study of newly tested glaucoma patients, Support the show

    First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma?
See All (270)

Ratings & Reviews

About

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

Information

You Might Also Like